Emmaus Life Sciences Stock Beta
| EMMADelisted Stock | USD 0.26 0.00 0.00% |
Emmaus Life Sciences fundamentals help investors to digest information that contributes to Emmaus Life's financial success or failures. It also enables traders to predict the movement of Emmaus OTC Stock. The fundamental analysis module provides a way to measure Emmaus Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emmaus Life otc stock.
Emmaus |
Emmaus Life Sciences OTC Stock Beta Analysis
Emmaus Life's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Emmaus Life Beta | 1.97 |
Most of Emmaus Life's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emmaus Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Emmaus Life Sciences has a Beta of 1.9736. This is 129.49% higher than that of the Pharmaceuticals sector and 41.99% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Emmaus Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emmaus Life's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Emmaus Life could also be used in its relative valuation, which is a method of valuing Emmaus Life by comparing valuation metrics of similar companies.Emmaus Life is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Emmaus Life will likely underperform.
Emmaus Fundamentals
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 49.41 M | ||||
| Shares Outstanding | 49.56 M | ||||
| Shares Owned By Insiders | 38.73 % | ||||
| Number Of Shares Shorted | 41.22 K | ||||
| Price To Earning | (1.60) X | ||||
| Price To Sales | 1.06 X | ||||
| Revenue | 20.61 M | ||||
| Gross Profit | 17.3 M | ||||
| EBITDA | (12.76 M) | ||||
| Net Income | (15.95 M) | ||||
| Cash And Equivalents | 982 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 4.65 M | ||||
| Debt To Equity | (0.04) % | ||||
| Current Ratio | 0.14 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (1.25 M) | ||||
| Short Ratio | 0.48 X | ||||
| Earnings Per Share | (0.18) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.97 | ||||
| Market Capitalization | 24.28 M | ||||
| Total Asset | 56.73 M | ||||
| Retained Earnings | (82.78 M) | ||||
| Working Capital | 1.95 M | ||||
| Current Asset | 9.19 M | ||||
| Current Liabilities | 7.25 M | ||||
| Z Score | 1.6 | ||||
| Net Asset | 56.73 M |
About Emmaus Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emmaus Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emmaus Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emmaus Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Emmaus OTC Stock
If you are still planning to invest in Emmaus Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emmaus Life's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |